Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6% – Here’s What Happened

Actuate Therapeutics, Inc. (NASDAQ:ACTU) shares traded down 3.6% on Monday . The stock traded as low as $4.17 and last traded at $4.25. 18,594 shares traded hands during trading, a decline of 72% from the average session volume of 67,262 shares. The stock had previously closed at $4.41.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ACTU shares. Wall Street Zen lowered Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Stock Down 3.6%

The firm has a market capitalization of $98.77 million, a price-to-earnings ratio of -4.89 and a beta of -0.15. The company has a 50-day moving average price of $6.10 and a 200-day moving average price of $6.84.

Actuate Therapeutics (NASDAQ:ACTU) last announced its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02.

Insiders Place Their Bets

In related news, Director Todd S. Thomson sold 280,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 904,795 shares in the company, valued at $5,247,811. This represents a 23.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 69.34% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ACTU. Voss Capital LP lifted its position in Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock worth $1,748,000 after purchasing an additional 143,759 shares during the period. BIOS Capital Management LP raised its stake in shares of Actuate Therapeutics by 0.7% in the 2nd quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock worth $60,887,000 after buying an additional 71,428 shares in the last quarter. Sfmg LLC lifted its holdings in shares of Actuate Therapeutics by 32.3% in the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after buying an additional 3,550 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after buying an additional 51,546 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Actuate Therapeutics by 492.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after buying an additional 15,393 shares in the last quarter.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.